This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
decarbazine 1000 mg/m2 IV Q 21 days x 12
CP-675,206 15 mg/kg IV Q 90 days x 4
temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
Ciudad de Buenos Aires, Buenos Aires, Argentina